IL285480A - Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells - Google Patents
Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cellsInfo
- Publication number
- IL285480A IL285480A IL285480A IL28548021A IL285480A IL 285480 A IL285480 A IL 285480A IL 285480 A IL285480 A IL 285480A IL 28548021 A IL28548021 A IL 28548021A IL 285480 A IL285480 A IL 285480A
- Authority
- IL
- Israel
- Prior art keywords
- amyloidosis
- antibody
- treatment
- combination
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804721P | 2019-02-12 | 2019-02-12 | |
| PCT/US2019/066648 WO2020167376A1 (en) | 2019-02-12 | 2019-12-16 | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL285480A true IL285480A (en) | 2021-09-30 |
Family
ID=69182616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL285480A IL285480A (en) | 2019-02-12 | 2021-08-09 | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20220213223A1 (https=) |
| EP (1) | EP3923954A1 (https=) |
| JP (2) | JP2022520572A (https=) |
| KR (1) | KR20210143752A (https=) |
| CN (2) | CN113924099A (https=) |
| AU (2) | AU2019429147B2 (https=) |
| BR (1) | BR112021015870A2 (https=) |
| CA (1) | CA3129890A1 (https=) |
| CL (1) | CL2021002140A1 (https=) |
| EA (1) | EA202192235A1 (https=) |
| IL (1) | IL285480A (https=) |
| JO (1) | JOP20210220A1 (https=) |
| MA (1) | MA54923A (https=) |
| MX (1) | MX2021009687A (https=) |
| PH (1) | PH12021551960A1 (https=) |
| SG (1) | SG11202108767PA (https=) |
| WO (1) | WO2020167376A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4582446A3 (en) | 2019-03-05 | 2025-08-13 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
| AU2005235811B2 (en) | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| DK2237803T3 (en) | 2007-12-28 | 2015-10-05 | Prothena Biosciences Ltd | Treatment and prophylaxis of amyloidosis |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| CN107233569B (zh) | 2011-10-25 | 2021-08-31 | 普罗西纳生物科学有限公司 | 抗体制剂和方法 |
| CN108771655A (zh) | 2011-10-28 | 2018-11-09 | 诚信生物公司 | 含有氨基酸的蛋白质制剂 |
| EA201792546A1 (ru) | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| CA3004152C (en) | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| ES2914781T3 (es) * | 2016-06-30 | 2022-06-16 | Prothena Biosciences Ltd | Composiciones para el tratamiento de la amiloidosis |
-
2019
- 2019-12-16 JP JP2021547075A patent/JP2022520572A/ja not_active Withdrawn
- 2019-12-16 CA CA3129890A patent/CA3129890A1/en active Pending
- 2019-12-16 BR BR112021015870A patent/BR112021015870A2/pt unknown
- 2019-12-16 AU AU2019429147A patent/AU2019429147B2/en active Active
- 2019-12-16 US US17/429,876 patent/US20220213223A1/en not_active Abandoned
- 2019-12-16 EP EP19839484.3A patent/EP3923954A1/en active Pending
- 2019-12-16 KR KR1020217029118A patent/KR20210143752A/ko not_active Ceased
- 2019-12-16 SG SG11202108767PA patent/SG11202108767PA/en unknown
- 2019-12-16 EA EA202192235A patent/EA202192235A1/ru unknown
- 2019-12-16 MA MA054923A patent/MA54923A/fr unknown
- 2019-12-16 CN CN201980094744.5A patent/CN113924099A/zh active Pending
- 2019-12-16 WO PCT/US2019/066648 patent/WO2020167376A1/en not_active Ceased
- 2019-12-16 MX MX2021009687A patent/MX2021009687A/es unknown
- 2019-12-16 CN CN202510068246.0A patent/CN119950702A/zh active Pending
- 2019-12-16 PH PH1/2021/551960A patent/PH12021551960A1/en unknown
-
2021
- 2021-08-09 IL IL285480A patent/IL285480A/en unknown
- 2021-08-11 JO JOP/2021/0220A patent/JOP20210220A1/ar unknown
- 2021-08-12 CL CL2021002140A patent/CL2021002140A1/es unknown
-
2024
- 2024-10-18 US US18/920,634 patent/US20250075007A1/en active Pending
- 2024-11-12 JP JP2024197437A patent/JP2025015588A/ja active Pending
-
2025
- 2025-02-13 AU AU2025200997A patent/AU2025200997A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20250075007A1 (en) | 2025-03-06 |
| WO2020167376A1 (en) | 2020-08-20 |
| KR20210143752A (ko) | 2021-11-29 |
| EA202192235A1 (ru) | 2022-01-19 |
| CL2021002140A1 (es) | 2022-04-18 |
| US20220213223A1 (en) | 2022-07-07 |
| PH12021551960A1 (en) | 2022-07-18 |
| AU2019429147A1 (en) | 2021-09-09 |
| CN113924099A (zh) | 2022-01-11 |
| WO2020167376A8 (en) | 2020-10-29 |
| MA54923A (fr) | 2021-12-22 |
| JOP20210220A1 (ar) | 2023-01-30 |
| AU2019429147B2 (en) | 2024-11-14 |
| BR112021015870A2 (pt) | 2021-11-03 |
| SG11202108767PA (en) | 2021-09-29 |
| CN119950702A (zh) | 2025-05-09 |
| JP2025015588A (ja) | 2025-01-30 |
| JP2022520572A (ja) | 2022-03-31 |
| CA3129890A1 (en) | 2020-08-20 |
| EP3923954A1 (en) | 2021-12-22 |
| AU2025200997A1 (en) | 2025-03-13 |
| MX2021009687A (es) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285480A (en) | Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells | |
| EA202092945A1 (ru) | Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии | |
| EA202190608A1 (ru) | Однодоменные анти-bcma антитела и их применение | |
| EA201991632A1 (ru) | Комбинация антитела против cd16a с цитокином | |
| EP4063497C0 (en) | ANTI-IMP TYPE CARBAPENEMASE HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE | |
| EP4048309A4 (en) | HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES | |
| JOP20180042A1 (ar) | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام | |
| EP4112723C0 (en) | ANTI-KPC TYPE CARBAPENEMASE HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND ITS APPLICATION | |
| EA202091364A1 (ru) | Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения | |
| SI3749338T1 (sl) | Humanizirano protitelo BCMA in celice BCMA-CAR-T | |
| EA201990570A1 (ru) | Моноклональное антитело против pd1, его фармацевтическая композиция и их применение | |
| EA202092417A1 (ru) | Химерные рецепторы к dll3 и способы их применения | |
| BR112019000431A2 (pt) | anticorpos contra tim3 e usos dos mesmos | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
| LT2005099A (en) | Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof | |
| MX393951B (es) | Anticuerpos antisortilina y métodos para su uso. | |
| HRP20200034T1 (hr) | Monoklonska protutijela protiv čimbenika rasta i diferencijacije 15 (gdf-15), te njihova upotreba u liječenju kaheksije uzrokovane rakom i raka | |
| AR052065A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
| MX2016005765A (es) | Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos. | |
| JOP20200240A1 (ar) | أجسام مضادة ضد- trem-1 واستخداماتها | |
| EP4319794A4 (en) | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING SAME | |
| EP4319768A4 (en) | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-HER2 ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING IT | |
| MX382703B (es) | ANTICUERPOS IGG MODIFICADOS QUE SE UNEN AL FACTOR DE CRECIMIENTO TRANSFORMANTE-ß1 CON ALTA AFINIDAD, AVIDEZ Y ESPECIFICIDAD. | |
| EA202190954A1 (ru) | Гуманизированное моноклональное антитело против n-укороченного бета-амилоида |